Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00242372 · ClinicalTrials.gov registry record · Phase 3
GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 370
- Enrollment target
NCT00242372 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 370 participants.
The verdict
NCT00242372, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 370 participants
- Enrollment target
Study Summary
This is a 24-week randomized, double-blind, multi-center, placebo-controlled study of tesaglitazar in patients with type 2 diabetes who are not adequately controlled on insulin (along or in combination with one or more oral antidiabetic agents in addition to diet and lifestyle advice). The study comprises a 3-week enrollment period and a 24-week randomized, double blind, multi-center, placebo-controlled treatment period and a 3-week follow-up. Patients must receive at least 30 units of insulin per day and will continue their current oral antidiabetic treatment regimen throughout the study.
Interventions
- DRUG Tesaglitazar 0.5
- DRUG Insulin at least 30 units/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2004-08 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00242372
The ClinicalTrials.gov registry entry for NCT00242372 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 370 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tesaglitazar 0.5 is the first listed.
NCT00242372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00242372 about?
NCT00242372 is a clinical study titled "GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin". This is a 24-week randomized, double-blind, multi-center, placebo-controlled study of tesaglitazar in patients with type 2 diabetes who are not adequately controlled on insulin (along or in combination with one or more oral antidiabetic agents in addition to diet and lifestyle advice). The study com...
What is the current status of trial NCT00242372?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 370 participants. The study started on 2004-08. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00242372?
The interventions under investigation include: Tesaglitazar 0.5 (DRUG), Insulin at least 30 units/day (DRUG).
Who is sponsoring clinical trial NCT00242372?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.